Artelo says ART27.13 matched semaglutide weight loss in animal model
The company reports its candidate doubled weight loss when combined with semaglutide in a nonclinical obesity model.
PR
By Priya Raman · Science Reporter
Sep 16 07:30 ETSource: Yahoo Finance UK
The wire
- 01Artelo Biosciences announced ART27.13 achieved weight loss comparable to semaglutide alone and doubled it in combination, in a nonclinical obesity model.
- 02Combination approaches are a key strategy for improving on GLP-1 monotherapy weight loss.
- 03Findings are preclinical; human data and trial plans were not detailed.
From the source
Read at news.google.comArtelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity